Effect of artificial liver support system on patients with severe viral hepatitis: A study of four hundred cases

Table 1 Types of severe hepatitis in two groups

Types	Treatment group		Control group
	Acute and subacute	Chronic	Acute and subacute	Chronic
A	6	0	8	0
B	17	310	20	313
C	0	14	0	10
E	2	0	1	0
B + D	0	12	0	13
A + B	8	18	9	16
B + E	5	7	3	5
B + C + D	0	1	1	1
Total	38	362	42	358

Table 2 Result of liver function test before and after ALSS therapy (mean ± SE)

Liver function	Pre-treatment	Post-treatment	P
ALT (U/L)	123.35 ± 281.32	53.15 ± 94.21	< 0.001
AST (U/L)	126.84 ± 115.25	63.71 ± 58.45	< 0.001
ALP (U/L)	127.97 ± 66.74	81.45 ± 39.62	< 0.001
TBil (μmol/L)	511.36 ± 192.81	257.38 ± 123.48	< 0.001
ChE (U/L)	2572.58 ± 2236.95	3119.24 ± 1812.62	0.001
γ -GT (U/L)	42.38 ± 53.85	20.91 ± 25.58	< 0.001
TBA (μmol/L)	256.36 ± 48.69	119.42 ± 49.37	< 0.001
PT (s)	31.8 ± 7.2	23.6 ± 6.8	< 0.001

Table 3 Serum amino acid levels in 25 cases before and after the first ALSS therapy (mean ± SE)

	Pre-therapy (μmol/L)	After therapy (μmol/L)
Cys	65.63 ± 41.40	53.74 ± 26.86a
Phe	94.78 ± 62.00	80.92 ± 40.75a
Ala	256.51 ± 123.73	267.84 ± 138.32
Gly	194.89 ± 83.43	212.50 ± 106.07
Glu	118.50 ± 89.65	116.85 ± 91.26
Gln	494.16 ± 218.91	515.84 ± 208.81
Met	185.85 ± 142.33	149.91 ± 134.16b
Arg	170.44 ± 231.69	143.18 ± 175.92a
Lys	220.72 ± 168.05	190.29 ± 136.28
Tyr	121.98 ± 82.82	104.44 ± 59.94a
Leu	73.73 ± 58.81	78.17 ± 43.74
Orn	113.99 ± 94.58	92.84 ± 52.93
Tau	46.41 ± 27.34	43.51 ± 32.90
Ser	123.78 ± 64.83	122.22 ± 61.29
Thr	165.60 ± 83.34	152.94 ± 83.42
Asp	16.22 ± 10.72	13.38 ± 7.87
Asn	59.40 ± 46.09	64.52 ± 49.46
Val	121.69 ± 75.01	126.35 ± 68.72
Ile	44.86 ± 36.61	46.29 ± 25.88
His	96.18 ± 73.85	87.86 ± 51.56
BCAA/AAA	1.18 ± 0.39	1.52 ± 0.77a

^aP < 0.05;

^bP < 0.001 vs pre-therapy group.

Table 4 Endotoxin, TNF, rIL-2R, IL-2 in patients with hepatic failure before and after ALSS therapy (mean ± SE)

	Pre-treatment	Post-treatment	P
Endotoxin (ng/L)	58.2 ± 12.3	32.4 ± 7.8	< 0.005
TNF (ng/L)	3.4 ± 1.2	3.2 ± 1.2	> 0.05
rIL-2R (U/mL)	1040.1 ± 309.2	951.0 ± 285.6	> 0.05
IL-2 (ng/mL)	20.1 ± 1.9	9.7 ± 1.8	> 0.05

Table 5 Prognosis of ALSS treatment group and control group

	ALSS treatment group				Control group
	Acute and subacute severe hepatitis		Chronic severe hepatitis		Acute and subacute severe hepatitis		Chronic severe hepatitis
	Cases	Ratio (%)	Cases	Ratio (%)	Cases	Ratio (%)	Cases	Ratio (%)
Cured	30	78.9	157	43.4	5	11.9	55	15.4
Discharged as their own will	2	5.3	107	29.6	16	38.1	122	34.0
Died	6	15.8	98	27.0	21	50.0	181	50.6
Total	38	100	362	100	42	100	358	100

Table 6 Outcome of patients in different stages after ALSS treatment

Stages	Cured		Discharged		Died		Total
	Cases	%	Cases	%	Cases	%
Early stage	52	76.5	9	13.2	7	10.3	68
Middle stage	115	61.8	34	18.3	37	19.9	186
End stage	20	13.7	68	46.6	58	39.7	146
Total	187	46.8	111	27.8	102	25.5	400